珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
2022年09月23日 15:53:33来源:作者:

Not intended for US-, Canada- or UK-based media

NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor
NMS-293 is currently studied in Phase I as monotherapy for the treatment of patients with BRCA-mutated tumors and in combination with temozolomide in recurrent glioblastoma
Next generation PARP1 selective inhibitors could fill a significant unmet patient need across a wide range of tumors including those not responsive to currently available PARP inhibitors and those requiring combination with other agents

DARMSTADT, Germany -- (BUSINESS WIRE) --

Merck, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types. NMS-293 is in early clinical development for the treatment of patients with BRCA-mutated tumors as a single agent and in combination with temozolomide in recurrent glioblastoma.

“Building on the therapeutic impact that PARP inhibitors have had over the last several years, we believe this new PARP1 program, if successful, could fill a significant unmet need for patients unresponsive to existing PARP inhibitors with an improved hematological adverse event profile,” said Victoria Zazulina, M.D., Head of Development Unit Oncology for the Healthcare business of Merck. “The work of NMS to discover and advance this next generation PARP1 selective inhibitor coupled with our deep expertise in developing therapies which modify DNA damage response mechanisms, creates a strong foundation to further develop this investigational therapy for patients.”

PARP is key in the repair of DNA damage, and PARP inhibitors have been shown to be highly efficacious in the treatment of patients with tumors deficient in homologous recombination repair, such as breast, ovarian, prostate and pancreatic cancers with BRCA-mutations.

Under the current agreement, Merck will make early payments (up-front and option exercise fees) of up to $65 million to NMS. Furthermore, NMS will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck. Upon exercise of the option, NMS will grant to Merck the exclusive rights to research, develop, manufacture, and commercialize NMS-293.

During the option period, NMS and Merck will collaborate on the clinical development of NMS-293, with NMS designing, sponsoring, conducting, and funding global clinical trials.

About NMS-293

NMS-293 is an orally available small molecule inhibitor of PARP1 and is currently in early clinical development for the treatment of patients with BRCA mutated tumors as single agent and with recurrent Glioblastoma (GBM), a brain tumor with very high medical need, in combination with temozolomide (TMZ).

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005113/en/

CONTACT:

noelle.piscitelli@emdserono.com
Phone: 1-781-427-4351

责任编辑: admin

看新闻,关注新闻

其它网友:不在乎  End.ゝ
评论:人=吃饭+睡觉+上班+玩,猪=吃饭+睡觉 ∴人=猪+上班+玩 ∴人-玩=猪+上班,不懂玩的人=会上班的猪

猫扑网友:心悲 2/2star°
评论:泰坦尼克号选在2012上映是要告诉我们,作为屌丝,就算你搞到了船票,也是死路一条。

凤凰网友:Curtain情歌
评论:我要多念一点书,哪怕以后当流氓,那咱也是有文化的流氓。

天猫网友:红衣a young woman
评论:赚钱像接露水那么辛苦,花钱却像流水那么迅速

淘宝网友:Pawonx-爱离殇
评论:我是一个很有原则的人,我的原则只有三个字,看心情

天涯网友:喜新 tunesd
评论:人生就像愤怒的小鸟,当你失败时,总有几只猪在笑。。。

本网网友:相依°- Janet
评论:从小就有一个敌人叫“别人家的小孩”。他不爱玩游戏,从来只知道学习。

搜狐网友:吓得魂飞魄散
评论:人生如梦,我总失眠;人生如戏,我总穿帮;人生如歌,我总跑调;人生如战场,我总走火。

腾讯网友:没你爸风骚 -
评论:每天都要做两件事情:晚上不想睡、早上不想起。

网易网友:Haggard. 憔悴
评论:你玩儿的叫潜水,哥玩儿的叫潜伏

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!